Crossject
- Biotech or pharma, therapeutic R&D
- Medical device or technology
Crossject is a specialty pharmaceutical company developing medicines for emergency situations utilizing its award-winning needle-free auto-injector ZENEO® platform and portfolio of drug /device combinations.
CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) (contract number 75A50122C0003).
The Company’s versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing.
Crossject's needle free auto-injection platform can be adapted to different liquid drug formulations in order to improve patients or caregiver usability, safety and injection reliability.
Crossject is currently ISO in-licensing opportunities synergistic to the ZENEO® auto injector in its IM and SC configurations.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}